Matthew J. Maurer, Sc.D., M.S.

Location

Contact

SUMMARY

Matthew J. Maurer, Sc.D., M.S., is a Mayo Clinic faculty biostatistician and lymphoma researcher. He leads the Lymphoma Biostatistics and Data Science Laboratory. Dr. Maurer's primary research interest is the evaluation of clinical endpoints and development of prognostic models and decision tools. He has more than 20 years of collaborative statistical experience across a broad range of research studies and clinical trials.

Focus areas

• Independent research program. Dr. Maurer's research program focuses on improving research efficiency and patient outcomes in lymphoma. He identifies and evaluates clinically relevant outcomes and studies clinical endpoints. Dr. Maurer develops risk prediction models and data-driven clinical tools for therapy selection. He improves clinical trial design and interpretation of clinical trial results. His findings include the evaluation of event-free survival at 24 months (EFS24) as a clinical endpoint in slow-growing and aggressive lymphomas. He identifies the importance of the number of days between diagnosing and treating aggressive lymphoma. Dr. Maurer develops prognostic indices and decision tools for frontline and relapsed-refractory lymphoma settings. These tools are available on the Mayo Clinic QHS Apps homepage, which links to apps produced by Mayo Clinic's Department of Qualitative Health Sciences, and the Lymphostats webpage, which highlights tools developed by Dr. Maurer's lab or in collaboration with lab members.
• Lymphoma Epidemiology of Outcomes (LEO) cohort study. The LEO cohort study is a multi-institutional, forward-looking epidemiology registry of information from people who are newly diagnosed with lymphoma. Funded by the National Cancer Institute, the cohort has enrolled and followed more than 20,000 people with lymphoma since 2002. Dr. Maurer oversees the data center for the Molecular Epidemiology Resource (MER) and the LEO cohort study and directs the examination of numerous studies using MER and LEO data.
• New endpoints and prognostic models for lymphoma. Through collaboration with national and international research groups, Dr. Maurer evaluates patterns of clinical outcomes and identification of unmet needs across a variety of lymphoma subtypes and clinical developments. He develops and contributes to multiple clinical risk models based on these observations.

Significance to patient care

Dr. Maurer works to improve treatments for people with lymphoma. He uses data from research studies and clinical trials, which test new treatments on patients, to understand the disease better. He creates tools to help doctors predict how lymphoma will progress and choose the best treatments. His goal is to make clinical trials more effective and improve how their results are used.

Professional highlights

• Temporary voting member, Oncologic Drugs Advisory Committee, U.S. Food and Drug Administration, 2024-present.
• Member, editorial board, Haematologica, 2022-present.
• Member, steering committee, Hodgkin Lymphoma International Study for Individual Care Consortium, 2022-present.
• Director, Statistics Core, Lymphoma Epidemiology of Outcomes cohort study, 2021-present.
• Faculty member, Clinical Research Training Institute, American Society of Hematology, 2020-present.
• Faculty member, Lymphoma Scientific Research Mentoring Program, Lymphoma Research Foundation, 2017-present.
• Co-director, Biostatistics and Bioinformatics Core, University of Iowa/Mayo Clinic Lymphoma Specialized Programs of Research Excellence, 2021-2023.